SEC Filings
Axsome's Trade Receivables Hit $371.3 Million, Up From $246.7 Million At Year-End, While The Company Still Loses Money
Customers owe Axsome far more than in December, and a few wholesalers account for most of its sales, the 10-Q shows.
AXSM
Axsome Therapeutics (AXSM) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
Axsome Stock Plunges 10%, Wiping Out $725 Million, Even As Quarterly Revenue Jumps 52%
Shares sank despite a much narrower third-quarter loss and rising Auvelity sales.
Earnings
Axsome Says Alzheimer's Agitation Launch Is Working, Won't Guide Fourth Quarter After Stock Slide
Executives cited prescription growth when pressed on a 40% to 45% stock drop since launch, and said Auvelity could reach $8 billion in peak sales.
Earnings
Axsome's Quarterly Net Loss Shrinks To $12.9 Million As Sales Climb 52%
The drugmaker's third-quarter product revenue hit $259.7 million, and it says current cash funds operations into cash flow positivity.